Sterling Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $133K | Buy |
1,056
+722
| +216% | +$90.7K | ﹤0.01% | 1317 |
|
|
2025
Q1 | $36.9K | Sell |
334
-1,278
| -79% | -$141K | ﹤0.01% | 1500 |
|
|
2024
Q4 | $220K | Sell |
1,612
-211
| -12% | -$28.8K | ﹤0.01% | 1243 |
|
|
2024
Q3 | $210K | Buy |
+1,823
| New | +$210K | ﹤0.01% | 1253 |
|
|
2018
Q4 | – | Sell |
-33,227
| Closed | -$4.09M | – | 904 |
|
|
2018
Q3 | $4.09M | Hold |
33,227
| – | – | 0.04% | 273 |
|
|
2018
Q2 | $3.26M | Hold |
33,227
| – | – | 0.03% | 301 |
|
|
2018
Q1 | $2.76M | Buy |
33,227
+16,919
| +104% | +$1.4M | 0.03% | 335 |
|
|
2017
Q4 | $1.27M | Buy |
+16,308
| New | +$1.27M | 0.01% | 536 |
|
|
2014
Q2 | – | Sell |
-18,625
| Closed | -$300K | – | 910 |
|
|
2014
Q1 | $300K | Buy |
+18,625
| New | +$300K | ﹤0.01% | 859 |
|